August 19, 2016
1 min read
Save
This article is more than 5 years old. Information may no longer be current.
Ocular Therapeutix reports $11.4 million net loss in second quarter
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Ocular Therapeutix reported a net loss of approximately $11.4 million, or $0.46 per share, in the second quarter of 2016 compared with a net loss of $10 million, or $0.45 per share, in the same quarter last year, according to a company press release.
Sales of ReSure Sealant generated about $441,000 in revenue, an increase of $107,000 over the same period last year.
Total costs and operating expenses increased from $10.1 million to $11.5 million in the same quarter last year, with the increases mainly attributed to costs associated with drug development and clinical trials, as well as increased sales and marketing expenses.
Research and development expenses increased from $6.7 million to $7 million.